. Author manuscript; available in PMC: 2014 May 22.

Published in final edited form as: Mol Cancer Ther. 2012 Apr 5;11(6):1365–1372. doi: 10.1158/1535-7163.MCT-11-0764

Table 2.

Pretargeted tumor/organ ratios.

	Time post-injection^a
Organ/tissue	4 h	24 h	48 h
Blood	18 ± 2	380 ± 90	> 450
Skin	1.7 ± 0.4	14 ± 2	20 ± 8
Adipose	3.2 ± 1.5	23 ± 6	28 ± 13
Muscle	5.3 ± 1.6	57 ± 41	105 ± 40
Bone (femur)	5.3 ± 1.6	38 ± 16	60 ± 19
Heart	49 ± 36	323 ± 108	244 ± 85
Lung	7.2 ± 3.7	39 ± 3	63 ± 6
Spleen	20 ± 5	52 ± 12	40 ± 21
Liver	13.9 ± 3.7	33 ± 11	32 ± 13
Kidneys (both)	8.1 ± 0.2	17 ± 3	22 ± 3
Stomach (with contents)	48 ± 22	252 ± 119	276 ± 236
Sm Intestine	27 ± 4	217 ± 76	183 ± 129
Lg Intestine	80 ± 36	83 ± 53	128 ± 16
C6 Tumor	0.7 ± 0.1	3.4 ± 0.3	10 ± 9
LS174T Tumor	1	1	1

Tumor/organ ratios (mean ± s.d., n=3) ^a Mice were injected with 500 ug bsAb i.v. 24 h later, mice received 250 ug dextran-DOTA i.v. 1 h later, mice received 100–150 uCi of ¹⁷⁷ Lu-DOTA i.v. and were sacrificed at 4, 24, and 48 h p.i.